Proviraplex 25 - Axio Labs

Mesterolone was first marketed by Schering in 1934 as Proviron®, preceding many other anabolic agents in clinical use. Developed in Germany during the early wave of hormone research, it was originally intended as a treatment for androgen deficiency. Though weaker in anabolic action, its potent androgenic profile and negligible suppression of gonadotropin release gave it a long-standing role in male therapy. Following Schering’s acquisition by Bayer in 2006, Proviron remained available in several international markets.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Proviraplex 25 by Axio Labs, consult with your doctor or healthcare professional.